Securities code: 002821 securities abbreviation: Asymchem Laboratories (Tianjin) Co.Ltd(002821) Announcement No.: 2022-001 Asymchem Laboratories (Tianjin) Co.Ltd(002821) Pharmaceutical Group (Tianjin) Co., Ltd
Actions on partial exercise of over allotment rights, price stabilization and
Announcement of the end of the price stabilization period
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and there are no false records, misleading statements or major omissions.
1、 Partial exercise of over allotment rights
Asymchem Laboratories (Tianjin) Co.Ltd(002821) 18415400 overseas listed foreign shares (H shares) issued by pharmaceutical group (Tianjin) Co., Ltd. (hereinafter referred to as the “company”) (before exercising the over allotment rights) were listed and traded on the main board of the stock exchange of Hong Kong Limited (hereinafter referred to as the “Hong Kong Stock Exchange”) on December 10, 2021 (hereinafter referred to as the “issuance and listing”).
According to the resolution adopted at the second extraordinary general meeting of shareholders in 2021 held by the company on June 16, 2021, the general meeting of shareholders of the company granted the underwriter (bookkeeper) an over allotment equity of no more than 15% of the number of H shares issued this time. According to the capital market situation, the joint global coordinator of the company’s issuance and listing has partially exercised the over allotment rights on January 2, 2022, involving a total of 1265500 H shares (hereinafter referred to as “over allotment shares”), which is equivalent to about 6.9% of the total number of offer shares initially available for subscription under the global offering before any over allotment rights are exercised. The company will issue and allot over allotted shares at HK $388.00 per H share (excluding 1% brokerage commission, 0.0027% SFC transaction levy and 0.005% SEHK transaction fee) (i.e. the offering price per H share under the global offering). The listing committee has approved the listing and trading of over allotted shares. It is expected that the over allotment shares will be listed and traded on the main board of the Hong Kong Stock Exchange at 9 a.m. on Wednesday, January 5, 2022.
Before and after the exercise of the over allotment rights, the changes of the company’s shares are as follows:
After this H-share issuance and listing
Class of shares (before exercising the over allotment rights) (after exercising the over allotment rights) quantity (share) proportion quantity (share) proportion
Domestic listed domestic capital 24466111893.0% 24466111892.6%
Shares (A shares)
Overseas listed foreign capital 184154007.0% 196809007.4%
Shares (H shares)
Total number of shares 263076518100.0% 264342018100.0%
The company will receive the net proceeds of approximately HK $473.8 million from 1265500 H shares to be issued and allotted due to the partial exercise of the over allotment right (after deducting the underwriting Commission and other estimated expenses related to the exercise of the over allotment right), and will use the net proceeds for the purposes set out in the section “future plans and use of proceeds” of the prospectus.
2、 Price stabilization action and end of price stabilization period
The company further announced that the price stabilization period for the global offering had ended on Sunday, January 2, 2022 (the 30th day from the deadline for submitting applications for the Hong Kong public offering). The price stabilization actions taken by Goldman Sachs (Asia) Co., Ltd., its affiliates or any person acting on its behalf during the price stabilization period are as follows:
(1) A total of 2762300 H shares were over allocated in the international offering, equivalent to about 15% of the total number of offer shares initially available for subscription under the global offering before the exercise of the over allotment right;
(2) During the price stabilization period, a total of 1496800 H shares (equivalent to about 8.1% of the total number of offer shares initially available for subscription under the global offering before exercising any over allotment rights) were purchased in the market at a price ranging from HK $295.60 to HK $388.00 per H share (excluding 1.0% brokerage commission, 0.0027% SFC transaction levy and 0.005% SEHK transaction fee), To facilitate the delivery of H shares to the allottee who agrees to delay the delivery of the relevant H shares it has subscribed for. The last purchase made by the stable price operator in the market during the stable price period is the purchase at the price of HK $323.80 per H share (excluding 1.0% brokerage commission, 0.0027% SFC transaction levy and 0.005% SEHK transaction fee) on Friday, December 31, 2021;
(3) The over allotment rights were partially exercised by the joint global coordinators (on behalf of the International Underwriters) on January 2, 2022, involving a total of 1265500 H shares, equivalent to about 6.9% of the total number of offer shares initially available for subscription under the global offering before exercising any over allotment rights.
Part of the over allotment rights that have not been exercised by the joint global coordinators (on behalf of the International Underwriters) have expired on Sunday, January 2, 2022.
3、 Public shareholding
Immediately after the end of the stable price period and partial exercise of the over allotment right, the company will continue to comply with the requirements of public shareholding and free circulation under article 8.08 (1) (b) of the listing rules.
It is hereby announced.
Board of directors of Pharmaceutical Group (Tianjin) Co., Ltd. January 4, 2002
